SYNTHETIC HUMANISED LLAMA NANOBODY LIBRARY AND USE (Research Tool for Drug and Diagnostic Development)
In May 2022, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), MPP signed two licensing agreements with the United States National Institutes of Health (NIH) for the development of 11 innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.
Among these COVID-19 technologies is a research tool for drug and diagnostic development:
Synthetic humanized llama nanobody library and use thereof to identify SARS-CoV-2 neutralizing antibodies:
NCATS scientists have built a library of antibodies called synthetic nanobodies to rapidly identify novel therapeutics. The library will help speed the identification and development of nanobodies into preclinical evaluation and clinical applications. The library’s diversity will increase the likelihood of identifying nanobodies against new SARS-CoV-2 variants, as well as future pandemic threats as they emerge. The researchers evaluated the library against the SARS-CoV-2 spike protein, which the virus uses to infect cells. They found that many types of nanobodies could block the virus spike protein, and the viral activity.
MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
|Aim of the licences
|To facilitate the manufacture and commercialisation of Covid-19 related health products and vaccines around the world
|One licence covers different patents and materials on technologies potentially relevant in the fight against COVID-19. The second licence specifically covers patents on the spike protein.
|Any product or vaccine that is covered by the Patents or Patent Applications or uses the Licensed Material.
|Field of use
|While one licence on the different technologies is granted for SARS-CoV-2 products for the WHO C-TAP program, the second licence, in relation to spike protein, refers to SARS-CoV-2 vaccines for the WHO C-TAP program.
|Continuing until the date the last Patent has lapsed, expired, or been invalidated
|Scope of the grant
|Non-exclusive right to grant royalty-bearing sublicences to develop the licensed patents/material into licensed products or vaccines, and to commercialise the licensed products or vaccines
|MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence